Galera Therapeutics to Present at BofA Securities 2020 Health Care Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that CEO Mel Sorensen, M.D. will present virtually at the BofA Securities 2020 Health Care Conference on May 12, 2020, at 9:40 a.m. EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that CEO Mel Sorensen, M.D. will present virtually at the BofA Securities 2020 Health Care Conference on May 12, 2020, at 9:40 a.m. EDT. The presentation will be accessible via a live audio webcast on Galera's Investors page, with an archived version available for 30 days post-event. Galera focuses on developing novel therapeutics to transform cancer radiotherapy, including their lead candidate, avasopasem manganese, currently in Phase 3 trials for reducing radiation-induced severe oral mucositis.
Details
News Market Reaction – GRTX
The recorded move for GRTX in the trading session of this news was -12.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., May 05, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will virtually present at the BofA Securities 2020 Health Care Conference on Tuesday, May 12, 2020, at 9:40 a.m. EDT.
A live audio webcast of the presentation will be accessible from the Investors page of Galera’s website, investors.galeratx.com. An archived version of the webcast will be available in the News & Events section of the Investors page of Galera’s website for 30 days following the event.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera’s lead product candidate is avasopasem manganese (GC4419), a highly selective small molecule superoxide dismutase (SOD) mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM). Avasopasem manganese is being studied in the Phase 3 ROMAN trial for its ability to reduce the incidence and severity of SOM induced by radiotherapy in patients with locally advanced head and neck cancer, its lead indication, and in the Phase 2a trial for its ability to reduce the incidence of esophagitis induced by radiotherapy in patients with lung cancer. The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem manganese for the reduction of SOM induced by radiotherapy. Galera is developing a second product candidate, GC4711, which successfully completed a Phase 1 trial in healthy volunteers. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.
Investor Contacts:
Christopher Degnan
Galera Therapeutics, Inc.
610-725-1500
cdegnan@galeratx.com
Chiara Russo
Solebury Trout
617-221-9197
crusso@soleburytrout.com
Media Contact:
Heather Anderson
6 Degrees
919-827-5539
handerson@6degreespr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.